OOIR: Observatory of International Research

Papers

(The TQCC of Drug Resistance Updates is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Editorial Board	358
Modulating undruggable targets to overcome cancer therapy resistance	255
Editorial Board	214
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer	168
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma	168
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea	145
Novel nanomedicines to overcome cancer multidrug resistance	138
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor	135
Unraveling the secrets: Evolution of resistance mediated by membrane proteins	131
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma	105
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer	103
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	102
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	100
Evolution of RND efflux pumps in the development of a successful pathogen	99
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China	96
Editorial Board	96
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer	95
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	94
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae	92
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance	89
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges	88
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs	85
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	78
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma	76
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC	74

Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer	73
Targeting anoikis resistance as a strategy for cancer therapy	71
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs	69
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond	67
Editorial Board	66
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds	61
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer	60
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress	57
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica	54
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights	53
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity	52
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma	52
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	50
Research progress on gene mutations and drug resistance in leukemia	49
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers	48
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	47
Editorial Board	45
Emergence of novel Klebsiella pneumoniae ST types with multidrug resistance in clinic	44
Editorial Board	44
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	43
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C	42
Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment	42
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance	41
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	41
Global distribution and genomic characteristics of carbapenemase-producing Escherichia coli among humans, 2005–2023	40
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer	39
Autophagy in cancer development, immune evasion, and drug resistance	39
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment	39
LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein	38
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma	37
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	36
CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer	36
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance	36
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins	36
Hypoxia as a driver of resistance to immunotherapy	36
Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation	34
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	33
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	32
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae	32
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance	32
Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer	32
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP	31
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability	30
Characterization of NMCR-3, NMCR-4 and NMCR-5, three novel non-mobile colistin resistance determinants: Implications for MCR-3, MCR-7, and MCR-5 progenitors, respectively	29
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA	29
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1	28
Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer	28